Clinical Trial Update: An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses [Phase 4]

View source ↗

Summary

This is an open-label, 18-month Phase 4 safety study of 5-fluorouracil 0.5% cream for actinic keratosis. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Fluorouracil Cream, 0.5% (fluorouracil cream, 0.5%)

Snippet

Sponsor: Sanofi | Conditions: Actinic Keratoses | Phase 4 | Status: COMPLETED